We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDPH
RNS Number : 9431A
Dechra Pharmaceuticals PLC
02 October 2020
2 October 2020
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 1 October 2020, Paul Sandland, Executive Director and PDMR exercised approved and unapproved options over ordinary shares of 1p each in the Company. The options were granted under the Dechra Pharmaceuticals Approved Option Scheme and Dechra Pharmaceuticals Unapproved Option Scheme as detailed below. The exercise of the options was subject to the achievement of performance conditions which were satisfied to the extent that the options vested at 100%. Paul Sandland sold 2,474 of the shares acquired, and retained the remaining 1,449 shares.
Hot Features
Premium
Date of Scheme Number of Option Price Number of shares Sale
Grant options sold Price
exercised
15 September Approved 923 GBP9.75 Nil N/A
2015
19 September Approved 526 GBP13.69 Nil N/A
2016
19 September
2016 Unapproved 2,474 GBP13.69 2,474 GBP32.23
Paul Sandland's total beneficial holding following these transactions is 6,518 ordinary shares which represents 0.006% of the total issued share capital.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
------------------------------------ ------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------------ ------------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ ------------------------------------------
3. Details of the Issuer
--------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ ------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ ------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ ------------------------------------------
b) Nature of the Exercise of options under the Company's
transaction Approved Option Scheme
------------------------------------ ------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP9.75 923
GBP13.69 526
------------------------------------ -------------------- --------------------
d) Aggregated information
* Aggregate volume
1,449
GBP11.18
* Price GBP16,200.19
* Total
------------------------------------ ------------------------------------------
e) Date of the transaction 2020.10.01
------------------------------------ ------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ ------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
------------------------------------ ------------------------------------------
2. Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------------ ------------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ ------------------------------------------
3. Details of the Issuer
--------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ ------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ ------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ ------------------------------------------
b) Nature of the Exercise of options under the Company's
transaction Unapproved Option Scheme
------------------------------------ ------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP13.69 2,474
------------------------------------ -------------------- --------------------
d) Aggregated information
* Aggregate volume
2,474
GBP13.69
* Price
GBP33,869.06
* Total
------------------------------------ ------------------------------------------
e) Date of the transaction 2020.10.01
------------------------------------ ------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ ------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
----------------------------------- ----------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status Director/PDMR
----------------------------------- ----------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------------- ----------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------------- ----------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------------- ----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-----------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
----------------------------------- ----------------------------------------------
b) Nature of the Sale of shares obtained under the Company's
transaction Unapproved Share Option Scheme
----------------------------------- ----------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP 32.23 2,474
----------------------------------- ----------------------- ---------------------
d) Aggregated information
* Aggregate volume 2,474
GBP 32.23
* Price GBP79,737.02
* Total
----------------------------------- ----------------------------------------------
e) Date of the transaction 2020.10.01
----------------------------------- ----------------------------------------------
f) Place of the transaction London Stock Exchange
----------------------------------- ----------------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKKBBKFBDKBKK
(END) Dow Jones Newswires
October 02, 2020 04:04 ET (08:04 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
